周剂量奥沙利铂联合卡培他滨治疗27例体力状况削弱的转移性结直肠癌临床观察

目的评价周剂量奥沙利铂联合卡培他滨作为一线方案治疗体力状况削弱的(ECOGPS≥1)转移性结直肠癌的疗效及毒副反应。方法27例晚期结直肠癌患者采用奥沙利铂联合卡培他滨治疗。奥沙利铂70mg/m2,静脉滴入,持续3h,第1、8天;卡培他滨750mg/m2,口服,每日2次,第1天到第14天,21天为1个周期,至少2个周期后评价疗效。按RECIST标准评价近期疗效和毒副反应效。结果可评价疗效和毒副反应27例,每例病人均接受2-6周期化疗,共86周期,CR1例,PR13例,总有效率51.85%(CR+PR)。毒副反应主要有骨髓抑制,外周神经感觉异常,手足综合征,口腔粘膜炎,恶心、呕吐和腹泻。全组无治疗相关性死亡。结论周剂量奥沙利铂联合卡培他滨治疗体力状况削弱(ECOGPS≥1)的转移性结直肠癌有较好的疗效,毒副反应可以耐受,值得进一步观察。

WEEKLY OXAUPLATIN PLUS CAPECITABINE FOR PATIENTS OF METASTATIC COLORECTAL CARCINOMA WITH IMPAIRED PERFORMANCE STATUS

obejective To determine the efficacy and toxicity of weekly oxaliplatin combined with capecitabine as first - line treatment in metastatic eolorectal carcinoma for patients with impaired performance status （ECOG PS ≥ 1）. Methods Twenty seven patients with metastatic colorectal carcinoma were eligible for the study. All patients were treated with oxaliplatin 70 mg/m^2 ,3 -hour intravenous infusion, d1 ,d8 ; capecitabinc was administered orally twice a day continuously for 14 days in dose 1 500 mg/（ m^2 . d） , repeated every three weeks. The effect was evaluated after two cycles. The efficacy and toxicity were evaluated according to RECIST standard. Results All the 27 patients might be evaluated for clinical response after having received 2 to 6 cycles of chemotherapy, totally 86 cycles. Complete response in lpts and partial response in 13 pts were observed with an overall response rate of 51.85% , The most common toxicities were bone marrow suppression, sensory neuritis, hand -foot syndrome, stomatitis, nausea,vomiting and diarrhea. There was no treatment related death. Conclusion Weekly oxaliplatin combined with capecitabine is effective and well- tolerated in patients with impaired performance status （ECOG PS≥1 ） and metastatic colorectal carcinoma.